Zanubrutinib for patients with previously untreated CLL/SLL: Insights from the SEQUOIA trial
カートのアイテムが多すぎます
カートに追加できませんでした。
ウィッシュリストに追加できませんでした。
ほしい物リストの削除に失敗しました。
ポッドキャストのフォローに失敗しました
ポッドキャストのフォロー解除に失敗しました
Zanubrutinib for patients with previously untreated CLL/SLL: Insights from the SEQUOIA trial
-
ナレーター：
-
著者：
During the Lymphoma Hub Steering Committee Meeting on April 20, 2026, key opinion leaders met to discuss results from the long-term follow-up of the phase III SEQUOIA trial (NCT03336333) evaluating zanubrutinib in patients with previously untreated chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). The discussion was chaired by Jacob Soumerai and featured Gilles Salles, Ulrich Jäger, Sonali Smith, Martin Dreyling, Astrid Pavlovsky, Michael Dickinson, and Jennifer Crombie.
Soumerai presented an overview of the SEQUOIA trial, efficacy and safety data, and key takeaways.
This educational resource is independently supported by BeOne Medicines. All content is developed by SES in collaboration with an expert steering committee. Funders are allowed no influence.
Hosted on Acast. See acast.com/privacy for more information.